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294 C.-F. Yeh et al.showed that yakammaoto reduced viral replication. Western blotting analysis showed that ya-
kammaoto can inhibit viral protein production. Thus, our results suggest that yakammaoto
should be considered to manage EV71 infection in the future.
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Enterovirus infection is common worldwide. It can cause
human diseases with various severity levels. The most se-
vere form of the disease involves infections of the central
nervous system (CNS) with mortality and neurologic
sequelae, such as flaccid paralysis [1]. Among the various
neurotropic enteroviruses, enterovirus 71 (EV71) is perhaps
the most catastrophic virus next to poliovirus. After the
effective control of poliovirus by vaccination, the impor-
tance of controlling EV71 is on the rise. EV71 usually causes
symptoms mimicking common airway infections and hand,
foot, and mouth disease (HFMD) [2]. However, EV71 can
cause brain stem encephalitis, neurogenic shock, and
neurogenic pulmonary edema [3,4]. A large outbreak of
EV71 occurred in Taiwan in 1998, with reports indicating
mortality in 78 cases [3]. Most of the victims were <5 years
of age. They all died of CNS infections and cardiopulmonary
failure [3]. In addition to this outbreak in Taiwan, a large
EV71 outbreak was reported in China [5] and fatal cases
were also reported in Asia as recently as 2012 [6,7].
Furthermore, survivors of CNS EV71 infection were found to
have neurological sequelae and delayed neurodevelopment
[8]. Therefore, effective management of this infection
could improve the quality of life of many children. At
present, there is no effective therapy available for treating
this infection [9]. However, several therapeutic agents are
under development [10]. EV71 is transmitted from person-
to-person mainly by the fecaleoral route [11]. EV71 is far
more easily transmitted in the developing countries
because of crowded environments and poor public hygiene.
These countries may not have adequate budgets to coun-
teract this disease during an overwhelming outbreak. A
cost-effective, readily available, effective therapeutic
modality is thus an urgent need.
Yakammaoto (as termed in Japan; Ye-Gan-Ma-Huang-
Tang, YGMHT, in Taiwan; and She-Gan-Ma-Huang-Tang or
Sheganmahuang Decoction in Mainland China) [12,13] is an
inexpensive, readily available, traditional prescription, with
reports indicating its use for the management of airway
symptoms since the period of the Eastern Han Dynasty of
China (25e220 AD). Data of thefingerprint of yakammaoto has
been presented in a previous study [12]. Among its nine in-
gredients, Ephedra sinica is helpful against poliovirus I
in vitro [14] and Zingiber officinale has antiviral activity
against rhinovirus [15]. EV71, poliovirus, and rhinovirus are
all members of the family Picornaviridae. Therefore,
yakammaoto is expected to show antiviral activities against
the members of the family Picornaviridae. Yakammaoto has
already been proven to be effective against coxsackievirus
B4 (CVB4) [12]. Both CVB4 and EV71 are enteroviruses.
Therefore, we hypothesized that yakammaoto might beeffective against EV71 as well. We used both the human
foreskin fibroblast cell line (CCFS-1/KMC) and human rhab-
domyosarcoma cell line (RD cells) to test this hypothesis.
Materials and methods
Preparation of a hot water extract of yakammaoto
All air-dried ingredients (medicinal plant materials) of
yakammaoto were purchased from various herb shops in
Southern Taiwan. The authenticity of these materials were
confirmed as described previously [12]. A hot water extract
of yakammaoto was prepared as follows [12]: 100 g of air-
dried ingredients of yakammaoto were decocted for 1
hour with 1000 mL of distilled water repeatedly three
times. The decoctions were collected, mixed, filtered
through gauze, concentrated under reduced pressure, and
lyophilized to dryness. The weight/weight yield of yakam-
maoto was 17.5%. The extract of yakammaoto was dis-
solved in Dulbecco’s modified Eagle’s medium (DMEM;
GIBCO BRL, Grand Island, NY, USA) supplemented with 2% or
10% fetal calf serum (FCS) to the final concentrations of
3 mg/mL, 10 mg/mL, 30 mg/mL, 100 mg/mL, and 300 mg/mL
for evaluating its bioactivity and up to 3000 mg/mL for
evaluating its cytotoxicity prior to the experiments.
Human cell lines and EV71
Human foreskin fibroblast cell line (CCFS-1/KMC) [16] and
rhabdomyosarcoma cell line (RD cell; American Type Culture
Collection, ATCC CCL-136, Manassas, VA, USA) were used to
culture EV71 (BrCr strain; ATCC VR-784). Human liver hepa-
tocellular carcinoma cell lines, HepG2 (ATCC HB-8065) and
Huh7 [17], human larynx epidermoid carcinoma cell line
(HEp-2; ATCC CCL-23), lung carcinoma cell line (A549; ATCC
CCL-185), and an immortalized proximal tubule epithelial
cell line from adult human normal kidney (HK-2; ATCC CRL-
2190) were used to test the cytotoxicity of the extract pre-
pared. The reagents and medium used for cell culture were
purchased from GIBCO BRL. Cells were propagated at 37C
under 5% CO2 in DMEM supplemented with 10% FCS and an-
tibiotics. The virus was propagated on 90% confluent cell
monolayer in DMEM with 2% FCS and antibiotics. The viral
titer was determined and expressed as plaque forming units
(pfu)/mL. The virus was stored at 80C until use.
Cytotoxicity assay
The cytotoxic effects of yakammaoto on proliferating cells
were assayed using XTT kit (Roche, Mannheim, Germany)
according to the manufacturer’s instructions [18]. The 50%
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lated by regression analysis of the doseeresponse curve
generated from the data.
Evaluation of antiviral effect of yakammaoto in
CCFS-1/KMC cells by plaque reduction assay
The antiviral activity of yakammaoto was examined by pla-
que reduction assay [18] using CCFS-1/KMC cells. In brief, 105
cells/well were plated in 12-well culture plates at 37C
under 5% CO2 for 24 hours and inoculated with a mixture of
200 pfu/well viruses and various concentrations of the
yakammaoto extract in triplicate at room temperature for 1
hour. Then, the overlay medium (DMEM þ 2% FCS in 1%
methylcellulose) was added. The cells were cultured for 3
more days. Themonolayer was then fixed with 10% formalin,
stained with 1% crystal violet, and the plaques formed were
counted. Ribavirin (Sigma-Aldrich, St. Louis, MO, USA) was
used as the positive control. The minimal concentration
required to inhibit 50% cytopathic effect (IC50) of yakam-
maoto was calculated using regression analysis of the dosee
response curve generated from the data.
Evaluation of the antiviral effect of yakammaoto in
RD cells by flow cytometry
RD cells (1  106/well) were plated overnight, inoculated
with a mixture of viruses [multiplicity of infection
(MOI) Z 0.002] and various concentrations of yakammaoto
in triplicate, and cultured for 48 hours. Then, the cells
were washed, detached by trypsin to a single-cell suspen-
sion, fixed with 4% paraformaldehyde, and permeabilized
using 20C methanol [19]. Viral particles were detected
by a 1:200-dilution of commercial monoclonal antibody
against viral VP0 and VP2 (MAB979; Chemicon, Temecula,
CA, USA) at 4C overnight, followed by a 1:50-dilution of
goat antimouse immunoglobulin G-FITC (Jackson Immu-
noResearch, West Grove, PA, USA) at 37C for 1 hour in the
dark. The infection rate was assessed as a function of
fluorescein isothiocyanate expression using flow cytometry
(BD FACSArray; BD Bioscience, San Diego, CA, USA). IC50 was
calculated as previously described.
Time-of-addition assay
The antiviral activity of yakammaoto was examined before
and after viral inoculation [18]. In brief, cells were seeded
and incubated for 24 hours as previously described. Yakam-
maoto extract of various concentrations was supplemented
at 1 hour or 2 hours before or after viral inoculation. The
supernatant was removed before the overlay medium was
added. The infected cultures were incubated for 72 hours.
After fixation and staining, plaques were counted.
Evaluation of attachment and internalization of the
virus by plaque counting
Yakammaoto was evaluated for its effect on viral attachment
[18]. In brief, cells were seeded and incubated for 24 hours.
The cellswere prechilled at 4C for 1 hour and themediumwasreplaced with a mixture of 200 pfu/well virus and various
concentrations of yakammaoto extract. After incubation at
4C for another 3 hours, the free viruses were removed. The
cell monolayer was washed with ice-cold phosphate-buffered
saline (PBS) three times, covered with overlay medium, incu-
bated for 72 hours, and then examined by plaque counting.
The effect of yakammaoto on viral internalization was
examined at 20-minute intervals following viral attachment
[18]. In brief, the cell monolayer was grown in 12-well cul-
ture plates and prechilled at 4C for 1 hour. Cells were
infected with EV71 (200 pfu/well) and incubated at 4C for 3
hours to allow for virus binding without internalization. The
virus-containing medium was replaced with fresh medium
containing various concentrations of yakammaoto extract
and the temperature was changed to 37C. At 20-minute
intervals following the temperature shift to 37C, acidic
PBS (pH 3) was supplemented for 1 minute to inactivate the
uninternalized virus, followedby addition of alkaline PBS (pH
11) for neutralization. Then, PBS was replaced by fresh
overlay medium. After incubation for 72 hours, the cell
monolayer was stained and examined by plaque counting.Reverse transcription-polymerase chain reaction
and quantitative reverse transcription-polymerase
chain reaction
The anti-EV71 activity of yakammaoto was further examined
using reverse transcription-polymerase chain reaction (RT-
PCR) and quantitative RT-PCR (qRT-PCR) after viral inocula-
tion. In brief, 1 106/well RD cells or CCFS-1/KMC cells were
plated into 6-well culture plates for 24 hours. Various con-
centrations of yakammaoto were supplemented with EV71
(MOI Z 0.002) simultaneously or 1 hour after viral inocula-
tion. After culture for 48 hours (for samples of cells with virus
infection and yakammaoto treatment at the same time) or 36
hours (for samples of cells treated with yakammaoto 1 hour
after virus infection), viral RNA was extracted from the cell-
culture supernatant or cells using QIAamp Viral RNA Mini Kit
(Qiagen, Heidelberg, Germany) or RNeasy Plus Mini Kit
(Qiagen), respectively. The complementary DNAs (cDNAs)
were synthesized from the eluted RNAs using the SuperScript
II RNase H-Reverse Transcriptase kit (Invitrogen, Carlsbad,
CA, USA). In brief, 0.5 mg RNAwas supplemented into a cDNA
synthesis master mixture containing 1 mL reverse transcrip-
tase, 2 mL dithiothreitol (DTT), 1 mL 10mM deoxyribonucle-
otide triphosphate, and 1 mL 10mM EV71 reverse primer (50-
ATTTCAGCAGCTTGGAGTGC-30) [20]. The reaction was car-
ried out at 42C for 60 minutes, followed by treatment at
70C for 15 minutes. Then, 4 mg of cDNA was supplemented
into a reaction tube containing 25 mL of 2 Taq Master Mix
(Vivantis, Saint Petersburg, Florida, USA), 2.5 mL 10mM EV71
forward primer (50-GCAGCCCAAAAGAACTTCAC-30), and the
same amount of reverse primer. This mixture was then sup-
plemented with nuclease-free water to make up a total
volume of 50 mL. The PCR condition was denaturized at 95C
for 10 minutes then followed by 25 cycles of amplification
at 95C (20 seconds), 45C (25 seconds), 72C (30 seconds),
and the final extension step at 72C for 10 minutes. The
amplification products were analyzed semiquantitatively
using 2% agarose gel electrophoresis. Using EZ-VISION DNA
Dye (AMRESCO, Solon, OH, USA) as the loading buffer, the
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molecular weight (226 bp; visualized using UVDOC HD2 sys-
tem, Uvitec Cambridge, Cambridge, UK). In quantitative
PCR, 2 mg cDNA was supplemented into a reaction tube con-
taining 10 mL Fast SYBR Green Master Mix (Applied Bio-
systems, Foster City, CA, USA) and 2.5 mL of each primer.
These were further supplemented with nuclease-free water
to make a total volume of 20 mL. The quantitative PCR con-
dition was as follows: 95C for 10 minutes, followed by 25
cycles of amplification at 95C for 15 seconds and 60C for 1
minute using the Step One Real-Time PCR System (Applied
Biosystems). 2delta Ct (threshold cycle) calculated as
Cttreated e Ctuntreated, obtained by measuring the differences
in Ct between the experimental group and the UV-inacti-
vated EV71 group.
Western blotting analysis for detecting viral
structure proteins
The efficiency of yakammaoto to inhibit viral protein trans-
lationwas evaluatedusingWestern blotting [21]. In brief, the
CCFS-1/KMCor RD cellswere supplementedwith amixture of
EV71 (200 pfu/well) and various concentrations of yakam-
maoto or ribavirin (30 mg/mL). To study the effect of treat-
ment of yakammaoto after infection on viral protein
translation, cells were treated with the drug 1 hour after
infection. After culture, the total cellular protein was
extracted using Roche Complete Lysis Kit (Roche Diagnostics
GmbH, Indianapolis, IN, USA) and its concentration was
determined using the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA). Then, 50 mg of total protein was mixed
with 5 sample buffer and boiled for 5 minutes at 95C [21].
Themixturewas separated on a 12% gel using sodiumdodecyl
sulfateepolyacrylamide gel electrophoresis (Bio-Rad). The
separated proteins were transferred to Hybond-P poly-
vinylidene difluoride membrane (Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK) and blocked with 5%
nonfat milk in Tris-buffered saline with Tween-20. VP0 and
VP2 were detected using a 1:1000 dilution of commercial
monoclonal antibody (MAB979; Chemicon), followed by a
1:2000 dilution of goat antimouse immunoglobulin
Gehorseradish peroxidase (HRP) conjugated antibody
(Jackson ImmunoResearch, West Grove, PA, USA). The in-
ternal control was b-actin, which was assayed using a 1:5000
dilution of monoclonal antibody (Chemicon) and detected
using the same secondary antibodymentionedearlier. Target
proteins were visualized using Immobilon Western Chemilu-
minescent HRP substrate (Millipore, Temecula, MA, USA) and
their autoradiographs were obtained using UVP ChemiDoc-It
810 Imaging System (UVP, Upland, CA, USA). The density
change of target protein was estimated using densitometry
(UVP ChemiDoc-It 810 Imaging System VisionWorksLS 7.1).
The percentage of density change was calculated from the
data of yakammaoto groups normalized by that of b-actin,
then divided by the normalized density of viral control.
Statistical analysis
Results were expressed as mean  standard deviation. The
percentage of control (infection rate; %) was calculated
from the data of yakammaoto groups divided by those ofthe viral control. The relative viral amount (fold change) of
qRT-PCR product was calculated from the data of yakam-
maoto groups divided by those of the UV-inactivated viral
control. Data were analyzed with analysis of variance
(ANOVA) using JMP 11 software (SAS, Cary, NC, USA). Tukey
honestly significant difference test was used to compare all
pairs of groups in the ANOVA test. A p value < 0.05 was
considered statistically significant.
Results
Cytotoxicity assay
Yakammaoto contains 12.5% (w/w) Flos farfarae (Tussilago
farfara) [12]. Flos farfarae has been found to contain toxic
pyrrolizidine alkaloids, mainly senkirkine and traces of sen-
ecionine, which are associated with liver injury [22e24].
Therefore, the hepatotoxicity of yakammaotowas examined
using HepG2 (Fig. 1A) and Huh7 cells (Fig. 1B) by XTT assay.
Yakammaoto at the dose of 3000 mg/mL showed hepatotox-
icity after 3 days of treatment. However, after prolonged
culture of>7 days, only 300 mg/mL of yakammaoto might be
toxic to HepG2 and Huh7 cells (p < 0.0001). In HepG2, the
estimated CC50 values were 2437.5 mg/mL on Day 3,
278.2 mg/mL on Day 7, 259.8 mg/mL on Day 10, and 237.1 mg/
mL on Day 14. Yakammaoto was less toxic to Huh7 cells. The
CC50 values were >3000 mg/mL on Day 3 and Day 7,
1656.4 mg/mL on Day 10, and 235.3 mg/mL on Day 14.
To determine whether yakammaoto was also toxic to
other cells, cytotoxicity assays were performed in CCFS-1/
KMC (a human foreskin normal fibroblast cell line), RD (a
human rhabdomyosarcoma cell line), HK-2 (a human normal
renal tubular cell line), A549 (a human lung carcinoma cell
line), and HEp-2 (a human larynx epidermoid carcinoma cell
line) cells with XTT. Yakammaoto showed minimal cyto-
toxicity at concentrations of 1000 mg/mL and 30 mg/mL on
CCFS-1/KMC cells and RD cells, respectively (p < 0.05;
Fig. 1C). RD cells were more sensitive to yakammaoto than
CCFS-1/KMC cells (p Z 0.0003). The estimated CC50 values
were >3000 mg/mL and 191.5 mg/mL in CCFS-1/KMC and RD
cells, respectively. Yakammaoto did not show any cyto-
toxicity against HK-2, A549, and HEp-2 cells (Fig. 1D) up to
the concentration of 3000 mg/mL.
Antiviral effect assay
To determine the anti-EV71 activity of yakammaoto, we
performed plaque reduction assay in CCFS-1/KMC cells and
flow cytometry in RD cells as demonstrated earlier. Yakam-
maoto dose dependently reduced plaque formation (Fig. 2A;
p< 0.0001) with a calculated IC50 of 73.3 mg/mL. The results
of flow cytometry indicated that yakammaoto also reduced
EV71 infection in RD cells (Fig. 2B; p < 0.0001) with a
calculated IC50 of 16.3 mg/mL. Yakammaoto at the dose of
30 mg/mL could decrease >90% EV71 infection in RD cells.
Time-of-addition assay
To understand whether yakammaoto showed a better anti-
EV71 activity when supplemented before or after EV71
Figure 1. Cytotoxicity of yakammaoto: 3000 mg/mL of yakammaoto extract showed a hepatotoxic effect on (A) HepG2 and (B)
Huh7 cells; 300 mg/mL yakammaoto might be toxic to HepG2 and Huh7 cells after use for >7 days. However, (C) 300 mg/mL
yakammaoto was toxic to RD cells on Day 3. Yakammaoto did not show any cytotoxicity against (D) HK-2, A549 and HEp-2 cells up to
the concentration of 3000 mg/mL on Day 3. Data are presented as mean  standard deviation of six tests. *p < 0.05; **p < 0.001;
***p < 0.0001 compared with the negative control.
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Yakammaoto dose dependently (Fig. 3; p < 0.0001) and
time dependently (p Z 0.027) inhibited EV71-induced pla-
que formation in CCFS-1/KMC cells with IC50 values of
70.4 mg/mL (2 hours after the infection), 60.6 mg/mL (1
hour after the infection), 88.7 mg/mL (1 hour before the
infection), and 79.7 mg/mL (2 hours before the infection).
Interestingly, yakammaoto showed its best inhibitory effect
when supplemented 1 hour after the EV71 infection.
Attachment assay and internalization assay
Yakammaoto showed its anti-EV71 activity when given prior
to viral inoculation (Fig. 3). Yakammaoto was expected to
inhibit viral attachment and/or internalization. To prove
these assumptions, an attachment assay and internalization
assay were performed. Yakammaoto dose dependently
inhibited EV71 attachment on CCFS-1/KMC cells (Fig. 4A;
p < 0.0001) with a calculated IC50 of 95.9 mg/mL. Yakam-
maoto also dose dependently and time dependently
inhibited EV71 internalization (Fig. 4B; p < 0.0001). The
IC50 values of the internalization assay were 112.1 mg/mL(20 minutes), 75.5 mg/mL (40 minutes), and 46.6 mg/mL (60
minutes).
RT-PCR and qRT-PCR
Yakammaoto showed its anti-EV71 activity when injected
after viral inoculation (Fig. 3). Yakammaoto was supposed
to work on viral replication and/or protein translation. To
prove these assumptions, RT-PCR and qRT-PCR were per-
formed. Yakammaoto dose dependently inhibited the
expression of viral RNA in CCFS-1/KMC (Fig. 5A; p < 0.0001)
and RD cells (Fig. 5B; p < 0.0001), both within the cells and
in the suspension. EV71 replicated more efficiently in RD
cellsd100-fold higher in the viral control of the RD cells
(Fig. 5B). With less efficient viral replication in CCFS-1/KMC
cells, 30 mg/mL yakammaoto could effectively inhibit viral
replication (Figs. 5A and 5C). By contrast, it took 100 mg/mL
to completely inhibit viral replication within RD cells (Figs.
5B and 5C). Yakammaoto showed similar inhibitory activity
on the intracellular EV71 RNA in both CCFS-1/KMC and RD
cells as demonstrated by qRT-PCR and RT-PCR assays.
However, the results are relatively inconsistent between
Figure 2. Antiviral effect assay. (A) Yakammaoto was dose-dependently effective in reducing EV71-induced plaque formation in
CCFS-1/KMC cells. (B) Flow cytometry revealed the anti-EV71 activity of yakammaoto in RD cells. Data are presented as
mean  standard deviation of nine tests in plaque reduction assay. *p < 0.05; **p < 0.001; ***p < 0.0001 compared with the viral
control. CCFS-1/KMC cellsZ human foreskin fibroblast cell line; EV71Z enterovirus 71; RD cellsZ human rhabdomyosarcoma cell
line.
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PCR assay, but not those of RT-PCR assay, demonstrated
that 30 mg/mL, 100 mg/mL, and 300 mg/mL yakammaoto
significantly reduced viral amount in the suspension. These
discrepancies between qRT-PCR and RT-PCR assays were
due to the fact that RT-PCR detects the end product after
25 cycles of amplification, whereas qRT-PCR calculates theFigure 3. Time-of-addition assay. Yakammaoto was dose-
dependently and time-dependently effective against EV71
infection in CCFS-1/KMC cells when given prior to or after EV71
inoculation. Data are presented as mean  standard deviation
of nine tests. *p < 0.05; **p < 0.001; ***p < 0.0001 compared
with the viral control. CCFS-1/KMC cells Z human foreskin
fibroblast cell line; EV71 Z enterovirus 71.threshold cycle. By analyzing the amplification plot of qRT-
PCR (data not shown), the threshold cycle can clearly
distinguish the viral amounts between groups, whereas the
end product was the same at the end of amplification.
Therefore, the qRT-PCR results were valid and more
convincing, although the results had some discrepancies.
The time-of-addition assay (Fig. 3) results indicated that
post-treatment was more effective than pretreatment. This
might imply an activity of yakammaoto against viral repli-
cation and translation. To confirm that yakammaoto can
inhibit viral replication, but not block viral attachment
and/or internalization to decrease viral RNA, yakammaoto
was supplemented 1 hour after viral inoculation. Yakam-
maoto effectively inhibited EV71 replication in CCFS-1/KMC
cells (Fig. 5D) and RD cells (Fig. 5E) by qRT-PCR. The RT-PCR
results (Fig. 5F) were similar to those of qRT-PCR with some
discrepancies as noted in the previous experiment (Fig. 5C).
Western blotting analysis for detecting viral
structure proteins
To prove that yakammaoto has an effect on viral protein
translation, Western blot assay was performed. The results
confirmed that yakammaoto was effective in blocking the
expression of VP0 and VP2 at a minimal concentration of
30 mg/mL in CCFS-1/KMC cells (Fig. 6A); 30 mg/mL yakam-
maoto could also clearly reduce the expression of VP2.
However, it took 100 mg/mL to completely block the
expression of VP0 and VP2 in RD cells (Fig. 6B). These
findings were compatible to those of PCR and suggest that
higher concentrations of yakammaoto were needed to
block EV71 activities in RD cells than in CCFS-1/KMC cells.
To confirm that the reduction of viral protein expression
is due to the inhibition of viral translation, but not due to
the blocking of viral attachment and/or internalization,
Figure 4. Attachment assay and penetration assay. Yakammaoto inhibited (A) viral attachment and (B) internalization in CCFS-1/
KMC cells. Data are presented as mean  standard deviation of nine tests. *p < 0.05; **p < 0.001; ***p < 0.0001 compared with the
viral control. CCFS-1/KMC cells Z human foreskin fibroblast cell line.
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lation. Yakammaoto dose dependently inhibited EV71
translation in CCFS-1/KMC cells (Fig. 6C) and RD cells
(Fig. 6D). It was also found that 30 mg/mL yakammaoto
could inhibit >20% viral protein production in both cells.
Approximately 100 mg/mL yakammaoto could inhibit 57%
VP0 and 62% VP2 production in RD cells, whereas 300 mg/mL
yakammaoto could reduce 87% VP0 and 56% VP2 production
in CCFS-1/KMC cells.Discussion
The current study demonstrates for the first time that
yakammaoto could effectively inhibit EV71 infection in
both CCFS-1/KMC and RD cells. Yakammaoto is a cost-
effective and readily available traditional prescription that
can be used to control EV71 infections in socioeconomically
disadvantaged families. Being a mixture, yakammaoto
could possibly work by inhibiting viral attachment, inter-
nalization, replication, and protein translation. In the
summer, EV71 infection commonly manifests as HFMD and/
or life-threatening cardiopulmonary diseases [3,8,25e28].
Infection of EV71 can spread into the CNS, subsequently
causing neuropathy and neural apoptotic cell death. This
spread of infection can damage vasomotor and respiratory
centers in the medulla, which may lead to autonomic ner-
vous system dysregulation and pulmonary edema [29,30].
However, the neuropathogenesis of EV71 infection is
currently unknown. Retrograde axonal spread along the
cranial or peripheral nerves is implicated to be the major
transmission route for EV71 neuroinvasion. Skeletal muscle
was found to serve as an important site for viral replication
and entry into the CNS [29,31]. Therefore, inhibition of
EV71 infection and its replication in skeletal muscle cells
might block the neuroinvasion. Indeed, 10 mg/mL yakam-
maoto started to decrease the infection rate (Fig. 2B) andviral transcription (Fig. 5B) in RD cells. This inhibition of
viral replication was also confirmed by supplementing
yakammaoto 1 hour after viral inoculation (Fig. 5E). With a
low IC50, yakammaoto might help to block the neuro-
invasion of EV71. VP0 and VP2 are structural proteins of
EV71. VP0 is produced during viral assembly of the repli-
cation cycle, which autocleaves into VP2 and VP4 to
generate infectious virions [21,32,33]. After cosupple-
menting with EV71, 30 mg/mL yakammaoto could inhibit the
viral protein translation and block the expression of VP0
and VP2 in RD cells (Fig. 6B). Besides, supplementing
yakammaoto 1 hour after viral inoculation also confirms this
activity. Therefore, yakammaoto could block the viral
replication, translation, maturation, and subsequent
release and infection. Furthermore, yakammaoto can also
prevent EV71 attachment and subsequent penetration into
host cells to initiate the second run of infection. Therefore,
yakammaoto could be beneficial to manage EV71 infection.
Yakammaoto consistently showed its anti-EV71 activity in
both human fibroblast and rhabdomyosarcoma cell lines.
The results were consistently demonstrated by different
methods. Within RD cells, 100 mg/mL yakammaoto can
almost completely inhibit EV71 as demonstrated by PCR
(Fig. 5C) and flow cytometry (Fig. 2B) results. Therefore,
our findings are valid, and support the use of yakammaoto
as an alternative choice for treating EV71 infection.
Enterovirus infection is more common in families with poor
socioeconomic status, living in a crowded space, and with
poor hygiene [26]. Yakammaoto is an inexpensive alterna-
tive that can reduce the financial impact to manage EV71
infection during endemic periods. If its efficacy can be
proven in clinical trials, yakammaoto could become a cost-
effective therapeutic modality against EV71 infection for
these socioeconomically disadvantaged families.
Yakammaoto contains 12.5% (w/w) flos farfarae [12],
which contains toxic pyrrolizidine alkaloids that may result
in liver injury [22,24]. Therefore, there are safety issues
Figure 5. Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative RT-PCR (qRT-PCR) assay. Yakammaoto dose-
dependently decreased viral amounts within the cells and in the suspension, compared with those of UV-inactivated EV71 (UV-EV71)
groups, by qRT-PCR in CCFS-1/KMC cells [(A) cosupplement and (D) supplemented 1 hour later] and RD cells [(B) cosupplement and (E)
supplemented 1 hour later] and by RT-PCR [(C) cosupplement and (F) supplemented 1 hour later]. Please note the different units for
the y axis between (A) and (B), and the different doses of yakammaoto used in CCFS-1/KMC and RD cells. Data are represented as
mean  standard deviation of three tests. *p < 0.05; **p < 0.001; ***p < 0.0001 compared with the control group. CCFS-1/KMC
cellsZ human foreskin fibroblast cell line; EV71Z enterovirus 71; RD cellsZ human rhabdomyosarcoma cell line.
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Figure 6. Western blot assay. Viral translation is clearly
inhibited at the highest tested concentration in both CCFS-1/
KMC cells [(A) cosupplement and (C) supplemented 1 hour
later] and RD cells [(B) cosupplement and (D) supplemented 1
hour later]. Please note the different doses of yakammaoto
used in CCFS-1/KMC and RD cells. CCFS-1/KMC cells Z human
foreskin fibroblast cell line; RD cells Z human rhabdomyosar-
coma cell line.
Yakammaoto inhibits EV71 infection 301regarding the use of yakammaoto. In studies, yakammaoto
did show some toxic effects to hepatocellular carcinoma
and rhabdomyosarcoma cell lines at high concentrations,
particularly after prolonged treatment (Fig. 1). However,
the regular prescription of yakammaoto in traditional use is
always at a low dose and for a short duration. Besides,
there is an alternative explanation. Yakammaoto may only
show its cytotoxic effect on cancer cell lines as several
ingredients of yakammaoto and their constituents have
antineoplastic activities [34e37]. The actual cytotoxic ef-
fects could be lower. Nevertheless, physicians should
monitor the liver function and be aware of myalgia.
Yakammaoto could still be a useful choice to manage EV71
infection.
In conclusion, yakammaoto is a readily available, inex-
pensive traditional prescription that could effectively
inhibit EV71-induced cell injuries by preventing viral
attachment, internalization, replication, and protein
translation. The current results support its possible use to
manage EV71 infection; however, physicians should care-
fully monitor the liver function and be aware of myalgia.Acknowledgments
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